Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2004-09-01
The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate
(DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with
menopause, and also to assess the effects of DVS on sleep parameters and health outcomes
indicators.
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-02-01
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability
of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects
receiving placebo.
Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
Terminated
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-03-01
The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment
of neuropathic pain associated with diabetic peripheral neuropathy.
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-03-01
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of
DVS SR versus placebo in subjects with Major Depressive Disorder. Additional objectives
include testing both general and functional quality-of-life outcomes and satisfaction with
therapy reported by the subject.
Study Evaluating the Effects of DVS SR and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
Completed
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3
2006-05-01
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and
paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
